History

2010–2015 Investing in the Future

2010

In June the Aspirin Social Award is presented for the first time. The award honors exemplary social projects in the health care sector.


2010

Fifty years of successful family planning with the pill: this innovative contraceptive was first given regulatory approval in 1960. Till this day Bayer is a global market leader in the field of hormonal contraception.


2011

In February, Bayer starts up the „Dream Production“ pilot plant in Leverkusen to manufacture high-tech plastics using carbon dioxide.


2012

In March, Bayer receives approval from the Australian Therapeutic Goods Administration (TGA) for Eylea™, an eye medicine for the treatment of wet age-related macular degeneration.


2013

In 2013, Bayer celebrates the 150th anniversary of its foundation worldwide. The company sends an airship and anniversary exhibition around the world, celebrates with German Federal Chancellor Angela Merkel, serves a celebratory meal for 110,000 employees and carries the Bayer spirit to more than 50 countries through the anniversary song “A Better Life.” more


2014

Bayer strengthens its oncology business with the acquisition of Algeta in March. In October, Bayer acquires the consumer care business of US-based Merck & Co., Inc. and engages in a strategic pharma cooperation in the field of sGC modulators. Furthermore Bayer strengthens its Consumer Care business in November with the acquisition of Dihon Pharmaceutical Group Co., Ltd. in China and Bayer HealthCare moves to a leading OTC position in this key growth country. In December Bayer CropScience acquires Land Management assets of DuPont Crop Protection in the United States, Canada, Mexico, Australia and New Zealand. The subgroup plays now a leading role in Industrial Vegetation Management.


2015

Bayer MaterialScience has been operating since 1 September under the name Covestro. The company is economically and legally independent, but initially remains a subsidiary of Bayer AG. On October 6, the Covestro AG made ​​her debut on the stock market.


2016

In May Werner Baumann becomes the new CEO of Bayer AG. Baumann has been a member of the Board of Management since January 2010 and was most recently responsible for Strategy and Portfolio Management.

In September Bayer and Monsanto sign a binding merger agreement. This creates the legal framework for the acquisition of Monsanto for a cash price of USD 128 per share. Monsanto stockholders vote in favor of the merger at an extraordinary stockholders’ meeting in December. The transaction is subject to the customary closing conditions, including the required regulatory approvals. More about the merger agreement


Last updated: April 11, 2017 Copyright © Bayer AG
https://www.bayer.com